Mileutis to Present at the 39th Annual J.P. Morgan Healthcare Conference

Mileutis Ltd.

Mileutis Ltd. (“Mileutis”), an Israeli biopharmaceutical company which helps mitigate the use of antibiotics in animals through its safe and residue-free immunomodulator peptides, today announced that its CEO, David Javier Iscovich is set to present a corporate presentation at the 39th Annual J.P. Morgan Healthcare Conference.

Mileutis is developing residue-free natural proteins based on early research conducted at Israel’s Agricultural Research Organization (Volcani Center), and at Mileutis. The company is developing a line of patented biopharmaceuticals that it believes will revolutionize the way veterinarians manage mastitis and treat a wide range of diseases. Mileutis’ claims are supported by statistically significant results in a number of case-controlled, randomized, multi-center clinical trials.

The first line of products is comprised of peptides and specific protein fragments that have a positive impact on conditions that influence health and reduce antibiotic use in animal health management and increases its wellbeing.

Mileutis is headed by its co-founder David Javier Iscovich, who serves as the company’s CEO. The R&D effort is being led by Dr. Jose Iscovich, president, and co-founder of the company.

Mileutis plans to introduce Imilac™, for use in the management, treatment, and prevention of bovine mastitis at dry-off, with estimated potential annual revenue of above $1 billion globally. Mastitis is the most frequent disease in dairy herds worldwide, and the most costly. The novel residue-free peptide developed by Mileutis is the first in a series of patented products targeting the growing concern of antibiotic resistance and overuse of antibiotics in the global dairy industry.





Be the first to comment

Leave a Reply

Your email address will not be published.


*